| dc.contributor.author | Chemtai Mungo, Katherine Sorgi, Cirillus Ogollah, Brenda Misiko, Cynthia Cheserem, George Githongo, Jackton Omoto | |
| dc.date.accessioned | 2024-10-29T17:17:10Z | |
| dc.date.available | 2024-10-29T17:17:10Z | |
| dc.date.issued | 2024-07-08 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/6177 | |
| dc.description | The article can be accessed in full via:https://www.medrxiv.org/content/10.1101/2024.07.08.24309596v2.full | en_US |
| dc.description.abstract | Cervical cancer remains a significant global health issue, especially in low- and middle-income countries (LMICs), where access to prevention and treatment is limited and women are at a higher risk of cervical cancer. Artesunate, a widely available drug used to treat malaria, has shown promise in treating human papillomavirus (HPV)-associated anogenital lesions including high-grade cervical precancer, in a recent Phase I studies in the United States. Data on the pharmacokinetics of artesunate following intravaginal use, and its implications on malaria resistance, are lacking. | en_US |
| dc.description.sponsorship | This research was supported by the Department of Obstetrics and Gynecology at University of North Carolina-Chapel Hill and the Womens Reproductive Health Research (WRHR) Career Development Program under award number 5-K12-HD103085-04. | en_US |
| dc.publisher | Cold Spring Harbor Laboratory Press | en_US |
| dc.subject | pharmacokinetics, artesunate, dihydroartemisinin, intravaginal use, cervical precancer, malaria resistance | en_US |
| dc.title | Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya | en_US |
| dc.type | Article | en_US |
